❮ Back to Researchers

Jiwon Oh

MD, PhD

Scientist

Email: Jiwon.Oh@unityhealth.to
Tel: 416-864-6060 ext. 2282

Research Programs

Biography

Research Interests

Multiple sclerosis (MS), MRI biomarkers with clinical utility in prognostication and disease monitoring, cohort studies

Research Activities

Jiwon Oh is a staff neurologist, scientist, and Medical Director of the Barlo Multiple Sclerosis (MS) Program at St. Michael’s Hospital, University of Toronto. Dr. Oh’s research focuses on developing advanced MRI techniques in the spinal cord and brain for use in clinical settings. She leads the MRI research program at St. Michael’s Hospital, and is the principal investigator on numerous local and multi-center collaborative studies, including the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo), which is a national prospective cohort study designed to better understand progression in MS.

Recent Publications

  1. Oh, J, Vukusic, S, Tiel-Wilck, K, Inshasi, JS, Rog, D, Baker, DP et al.. Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies. J Cent Nerv Syst Dis. 2021;13 :11795735211028781. doi: 10.1177/11795735211028781. PubMed PMID:34377047 PubMed Central PMC8330455.
  2. Oh, J, Walker, B, Giovannoni, G, Jack, D, Dangond, F, Nolting, A et al.. Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. Mult Scler J Exp Transl Clin. ;7 (3):20552173211024298. doi: 10.1177/20552173211024298. PubMed PMID:34345436 PubMed Central PMC8283088.
  3. Bittner, S, Oh, J, Havrdová, EK, Tintoré, M, Zipp, F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain. 2021; :. doi: 10.1093/brain/awab241. PubMed PMID:34180982 .
  4. Reyes, S, Cunningham, AL, Kalincik, T, Havrdová, EK, Isobe, N, Pakpoor, J et al.. Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. J Neuroimmunol. 2021;357 :577627. doi: 10.1016/j.jneuroim.2021.577627. PubMed PMID:34139567 PubMed Central PMC8183006.
  5. Wattjes, MP, Ciccarelli, O, Reich, DS, Banwell, B, de Stefano, N, Enzinger, C et al.. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20 (8):653-670. doi: 10.1016/S1474-4422(21)00095-8. PubMed PMID:34139157 .
  6. Solomon, JM, Paul, F, Chien, C, Oh, J, Rotstein, DL. A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. Ther Adv Neurol Disord. 2021;14 :17562864211014389. doi: 10.1177/17562864211014389. PubMed PMID:34035837 PubMed Central PMC8111516.
  7. Kuczynski, AM, Oh, J. Ozanimod for the treatment of relapsing forms of multiple sclerosis. Neurodegener Dis Manag. 2021;11 (3):207-220. doi: 10.2217/nmt-2021-0005. PubMed PMID:34011158 .
  8. Petzold, A, Albrecht, P, Balcer, L, Bekkers, E, Brandt, AU, Calabresi, PA et al.. Artificial intelligence extension of the OSCAR-IB criteria. Ann Clin Transl Neurol. 2021;8 (7):1528-1542. doi: 10.1002/acn3.51320. PubMed PMID:34008926 PubMed Central PMC8283174.
  9. Giacomini, PS, Oh, J, Morrow, SA, Beauchemin, P, Clift, F, Devonshire, V et al.. Videoconferencing and Multiple Sclerosis Management: Stopgap or Stay Tuned?. Can J Neurol Sci. 2021; :1-4. doi: 10.1017/cjn.2021.113. PubMed PMID:33998416 .
  10. Lincoln, MR, Schneider, R, Oh, J. Vitamin D as disease-modifying therapy for multiple sclerosis?. Expert Rev Clin Immunol. 2021;17 (7):691-693. doi: 10.1080/1744666X.2021.1915772. PubMed PMID:33836645 .
Search PubMed

Affiliations & Other Activities

  • Staff Neurologist, Division of Neurology, Department of Medicine, St. Michael’s Hospital
  • Associate Professor, Department of Medicine, University of Toronto
  • Adjunct Faculty, Department of Neurology, Johns Hopkins University
X